Brachytherapy Boost for Gleason (GS) 7 Intermediate-Risk Prostate Adenocarcinoma Yields Excellent Biochemical Control and May Eliminate Therapeutic Benefit of Hormonal Therapy

Autor:	R. Salant, J. Santoro, Daniel Shasha, E. Katsoulakis, M. Ryniak, R. Ambrose, J.N. Lukens, J. Dolan, C. Dinlenc, R. Woode, Catherine Concert, Rania A. Shourbaji, E. Goluboff, Mauricio E. Gamez, T. Nabhani, Waleed F. Mourad, Louis B. Harrison, R. Patel, S. Patel, N. Shah
Rok vydání:	2014
Předmět:	Oncology Prostate adenocarcinoma Cancer Research medicine.medical_specialty Radiation business.industry medicine.medical_treatment Brachytherapy Internal medicine medicine Hormonal therapy Radiology Nuclear Medicine and imaging Intermediate risk business
Zdroj:	International Journal of Radiation Oncology*Biology*Physics. 90:S427-S428
ISSN:	0360-3016
DOI:	10.1016/j.ijrobp.2014.05.1352
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4afbe92e550c888b9b6389cf95781b7c https://doi.org/10.1016/j.ijrobp.2014.05.1352 Zobrazit plný text záznamu